Hot Biotech Movers: VIVUS (NASDAQ:VVUS), MannKind Corporation (NASDAQ:MNKD), Arena Pharmaceuticals (NASDAQ:ARNA), Ariad Pharmaceuticals (NASDAQ:ARIA)

Technology Stocks News 4

VIVUS Inc (NASDAQ:VVUS) will be announcing its Q114 earnings results on Monday, May 5th. Analysts expect the company to announce earnings of ($0.37) per share and revenue of $11.40 million for the quarter. VIVUS, Inc. (NASDAQ:VVUS) stock performance was -2.12% in last session and finished the day at $5.09. Traded volume was 1.34million shares in the last session and the average volume of the stock remained 3.47million shares. The beta of the stock remained 1.32. VIVUS, Inc. (NASDAQ:VVUS) insider ownership is 0.10%.

A month ago, trading MannKind Corporation (NASDAQ:MNKD) would have been – and was – a nightmare. From a close of $5.20 on March 27th to a close of $4.02 on March 31st to a high of $8.08 on April 2nd to a close of $6.32 on April 7th, MNKD has been all over the map. MannKind Corporation (NASDAQ:MNKD) dropped -1.68 percent to $6.44 Thursday on volume of 5.02million shares. The intra-day range of the stock was $6.38 to $6.56. MannKind Corporation (NASDAQ:MNKD) has a market capitalization of $2.48billion.

Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) reported that Eisai Inc. has launched a national television advertising campaign for BELVIQ® (lorcaserin HCl), an FDA-approved prescription treatment for chronic weight management. The initial advertisement, which illustrates the struggles that many people face with hunger and body weight, will air on Lifetime, Oxygen, AMC and numerous other networks. BELVIQ is presented as a targeted approach to weight loss, that, when combined with diet and increased activity, may help patients lose weight and keep it off. Arena Pharmaceuticals, Inc. (NASDAQ:ARNA)’s stock on May 1, 2014 reported a increase of 4.06% to the closing price of $6.66. Its fifty two weeks range is $4.05 -$9.25. The total market capitalization recorded $1.46billion. The overall volume in the last trading session was 6.69million shares. In its share capital, ARNA has 219.26million outstanding shares.

Ariad Pharmaceuticals Inc (NASDAQ:ARIA) saw a significant growth in short interest during the month of April. As of April 15th, there was short interest totalling 42,213,990 shares, a growth of 6.4% from the March 31st total of 39,661,474 shares. On Thursday, shares of Ariad Pharmaceuticals, Inc. (NASDAQ:ARIA) advanced 2.82% to close the day at $7.47. Company return on investment (ROI) is -93.20% and its monthly performance is recorded as -12.21%. Ariad Pharmaceuticals, Inc. (NASDAQ:ARIA) quarterly revenue growth is -4.59%.

Signup for free to be the first to receive exclusive free links. Now in your mailbox!
Join over 15,000 subscribers
Send me links

Your information will not be shared to anyone